Objective: In this study, we intended to investigate the association between severity of PD motor symptoms and the cerebrospinal fluid (CSF) levels of CRP using the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale Part 3 (MDS-UPDRS3) score and the Hoehn and Yahr (H&Y) stage.

Background: Parkinson disease (PD) is the second most prevalent neurodegenerative disorder chiefly branded by bradykinesia, resting tremor, postural instability, and rigidity. PD is pathologically characterized with Lewy bodies deposition and dopaminergic loss in substantia nigra. Neuroinflammatory mechanisms including microglial activation and increased levels of inflammatory cytokines has been indicated in PD pathogenesis. One of the most notable inflammatory proteins is c-reactive protein (CRP), which is elevated in the conditions of systemic inflammation.

Methods: PD patients and healthy controls (HC) participating in this study were obtained from the BioFIND study. BioFIND is a comprehensive cross‐sectional observational project, which studies moderate to advanced PD patients and HCs in agreement with standardized clinical and biospecimen collection protocols.Using the data of BioFIND database, we aimed to scrutinize the possible association between PD motor symptoms (MDS-UPDRS3 and Hoehn and Yahr (H&Y) stage) and CSF levels of CRP. Eighty-four HCs and 109 PD subjects were entered into this study.

Results: Our findings demonstrated that MDS-UPDRS3 was able to predict CRP only in female group (b=0.311, P<0.05), but not in the male group. In contrast, H&Y could strongly predict CRP in both male and female groups (β=0.362, P<0.01 for male patients and β=0.432, P<0.01 for female patients).

Conclusions: In conclusion, in this study, we demonstrated that CSF CRP, the marker of neuroinflammation is correlated with some of the motor symptoms in individuals with PD. H&Y was in strong association with CRP levels, while MDS-UPDRS3 was correlated with CRP only in females. Our findings suggest that neuroinflammation biomarkers can be utilized as diagnostic or prognostic markers in PD patients. However, further research is required to enter neuroinflammation biomarkers into routine clinical assessments of PD patients.

« Back to 2018 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/motor-symptoms-in-patients-with-parkinsons-disease-correlations-with-cerebrospinal-fluid-c-reactive-protein/